Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget’s disease of bone
Open Access
- 15 June 2000
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 105 (12) , 1833-1838
- https://doi.org/10.1172/jci9133
Abstract
Paget’s disease is characterized by highly localized areas of increased osteoclast (OCL) activity. This suggests that the microenvironment in pagetic lesions is highly osteoclastogenic, or that OCL precursors in these lesions are hyperresponsive to osteoclastogenic factors (or both). To examine these possibilities, we compared RANK ligand (RANKL) mRNA expression in a marrow stromal cell line developed from a pagetic lesion (PSV10) with that in a normal stromal cell line (Saka), and expression in marrow samples from affected bones of Paget’s patients with that in normal marrow. RANKL mRNA was increased in PSV10 cells and pagetic marrow compared with Saka cells and normal marrow, and was also increased in marrow from affected bones compared with uninvolved bones from Paget’s patients. Furthermore, pagetic marrow cells formed OCLs at much lower RANKL concentrations than did normal marrow. Anti–IL-6 decreased the RANKL responsivity of pagetic marrow to normal levels, whereas addition of IL-6 to normal marrow enhanced RANKL responsivity. Thus, RANKL expression and responsivity is increased in pagetic lesions, in part mediated by IL-6. These data suggest that the combination of enhanced expression of RANKL in affected bones and increased RANKL sensitivity of pagetic OCL precursors may contribute to the elevated numbers of OCLs in Paget’s disease.Keywords
This publication has 24 references indexed in Scilit:
- Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cellsBone, 1999
- STAT3 Activation in Stromal/Osteoblastic Cells Is Required for Induction of the Receptor Activator of NF-κB Ligand and Stimulation of Osteoclastogenesis by gp130-utilizing Cytokines or Interleukin-1 but Not 1,25-Dihydroxyvitamin D3 or Parathyroid HormoneJournal of Biological Chemistry, 1999
- Paramyxoviruses and Paget’s disease: the affirmative viewBone, 1999
- Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 1998
- Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesis in VitroEndocrinology, 1998
- IL-6 Mediates the Effects of IL-1 or TNF, but Not PTHrP or 1,25(OH)2D3, on Osteoclast-like Cell Formation in Normal Human Bone Marrow CulturesJournal of Bone and Mineral Research, 1998
- Interleukin-6, IL-6 receptor, and IL-6 nuclear factor gene expression in paget's diseaseJournal of Bone and Mineral Research, 1994
- Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone.Journal of Clinical Investigation, 1992
- Atypical multinucleated cells form in long-term marrow cultures from patients with Paget's disease.Journal of Clinical Investigation, 1990
- Paget's disease of bone.BMJ, 1981